The di-allelic HLA-A2 restricted minor histocompatibility Ag HA-1 locus codes for the highly immunogenic HA-1
M
inor histocompatibility Ags play important roles in the outcome of stem cell transplantation (SCT) 5 and organ transplantation. In HLA-identical SCT minor histocompatibility Ags are involved in the development of graft-versushost disease and in the graft-versus-tumor reactivity (1) . Minor histocompatibility Ags are peptides from polymorphic cellular proteins encoded by autosomal genes and by genes of the Y chromosome (2) . Minor histocompatibility peptides are presented by MHC class I and class II molecules and are capable of inducing strong T cell immune responses between minor histocompatibility Ag disparate individuals. One important characteristic of minor histocompatibility Ags is their expression pattern; some minor histocompatibility peptides are ubiquitously expressed on all body cells, whereas others show a restricted tissue distribution (3) . Therefore, these two minor histocompatibility Ag types have discriminative roles in graft-versus-host disease and graft-versus-tumor reactivity: the broad minor histocompatibility peptides are involved in both disorders, whereas the restricted peptides are crucial for the graft-versus-tumor responses. The HA-1 minor histocompatibility Ag is hematopoietic system specific but shows additional expression on epithelial cancer cells while absent on the normal epithelial cell counterpart (4, 5) . Consequently, this minor histocompatibility Ag can be applied as an immunotherapeutic tool in SCT such as in cellular adoptive immunotherapy with HA-1-specific CTLs or in boosting the graft-versus-tumor responses with HA-1 peptide (6) . Indeed, the HA-1 peptide has recently entered a clinical phase I/II study for boosting the antileukemic and antisolid tumor responses after HLA matched minor histocompatibility Ag HA-1 mismatched SCT for hematologic malignancies and solid tumors, respectively (E. Goulmy and L. Hambach, unpublished observations).
The first identified and most studied HA-1 T cell epitope is an HLA-A2-restricted nonapeptide derived from a protein encoded by a polymorphic locus comprising two distinct alleles that differ by one amino acid (6) . The allele with a histidine at position 3 (HA-1 His , VLHDDLLEA) functions as a T cell epitope in the context of HLA-A2, whereas the other allele with arginine at position 3 (HA-1 Arg , VLRDDLLEA) does not. To explain the absence of the HA-1 Arg immunogenicity, we earlier determined the IC 50 binding values, half maximum lysis values, and the number of copies per cell of both the HA-1
His and the HA-1 Arg peptides. A noteworthy difference between the two alleles was solely observed in the estimated number of copies/cell, i.e., 80 for HA -1 His and less than 5 for HA-1 Arg (6) . Among the prevalent class I HLA molecules found in the Caucasian population studied, HLA-B60 also showed a strong and stable binding with both alleles of another HA-1 derived nonameric peptide (KECVL H / R DDLL) (7) . However, albeit the immunogenicity of these two HLA-B60-restricted peptide alleles remains to be precisely determined, the T cell response to HA-1
His is clearly immunodominant in HLA-A2 ϩ individuals, when compared with other HLA-A2-restricted minor histocompatibility Ags (8 -10) . To elucidate the mechanisms underlying the differential cell surface presentation of the HA-1 allelic peptides, we investigated the impact of the HA-1
His/Arg polymorphism on molecular and cellular processes involved in the intracellular generation and stable cell surface presentation of HLA class I-bound peptides. Crucial processes for proper generation of MHC class I-restricted peptides comprise precursor protein ubiquitinilation, degradation by proteasomes into peptides and peptide translocation into the endoplasmic reticulum (ER), trimming by proteases in the ER as well as the peptide binding capacity to HLA molecules (11) . In addition, the peptide immunogenicity has been shown to correlate with both its dissociation rate from and its affinity for the MHC molecule (12) (13) (14) (15) . Therefore, proteasome-mediated digestion experiments, TAP translocation analyses, and HLA-dissociation assays with HA-1 His and HA-1
Arg peptides were performed. Moreover, the crystal structures of HLA-A2 in complex with HA-1
His , HA-1 Arg , or a HA-1 variant with a citrulline residue at position 3 (HA-1 Cit ) were determined to obtain atomic level insights into the conformation of the HLA-A2/HA-1 peptide complexes. Indeed, because the citrulline differs from the arginine only by the replacement of one of the arginine guanidino nitrogen atoms by an oxygen atom (see data in supplemental Fig. S1 ), 6 it is sterically very similar to the arginine but uncharged. Our results exclude a role for Ag processing in preventing HA-1
Arg to be presented at the cell surface and clearly show by both the structural and HLA dissociation data that the lack of cell surface expression essentially results from an increased instability of the HA-1
Arg allele in the HLA-A2 peptide binding groove. The in vivo and in vitro stability demonstration of the HLA-A2/HA-1
His ligand in combination with its extensively proven immunogenicity strongly support its use as a therapeutic tool in SCT therapy for hematologic malignancies and solid tumors.
Materials and Methods

T cell clones
The HLA-A2-restricted HA-1-specific CD8 ϩ CTL clones 3HA15 and 5W38 were both isolated from patients after HLA-identical SCT (8, 16) . These CTLs were maintained and used in cytotoxicity and T cell epitope reconstitution assays as previously described (17) .
Synthetic peptides
Peptides were synthesized on a Syro II multiple peptide synthesizer (MultiSyntech) using solid-phase Fmoc chemistry and Tentagel resins. Peptides were HPLC purified to Ͼ98% on a C18 reversed phase column using a water/acetonitrile/trifluoroacetic acid system. Identity of all synthetic peptides was confirmed using electrospray ionization mass spectrometry on an LCQ mass spectrometer.
Fluorescent peptides were synthesized by replacing leucine at position 7 with a fluorescence-labeled cysteine-derivative (C*). These replacements were shown not affect peptide binding to HLA-A*0201 in competitionbased binding assays (data not shown). Fluorescent labeling was performed with 4-(iodoacetamido)-fluorescein (Fluka Chemie) at pH 7.5 (sodium phosphate in a water to acetonitrile ratio of 1:1). The fluorescent peptides were desalted over Sephadex G-10, purified by C18 reverse phase HPLC and analyzed by MALDI mass spectrometry.
Proteasomal digestion assays
20S proteasomes from HeLa, containing mostly constitutive proteasomes, and EBV-LCL ROF, containing mostly immunoproteasomes, were prepared and purified (purity Ͼ95%) as described (18) . To determine the proteasome-mediated cleavage, 10 g of 28 or 32 amino acid long, Ͼ98% pure HA-1
His and HA-1 Arg synthetic peptides were incubated with 1 g of purified 20S (immuno)proteasomes in 100 l of assay buffer (20 mM HEPES/KOH (pH 7.8), 2 mM MgAc 2 , 5 mM DTT) at 37°C for different time periods ranging from 15 min to 24 h. The proteolysis products were analyzed by electrospray ionization mass spectrometry on a hybrid quadrupole time of flight mass spectrometer (Micromass), equipped with an online nanoelectrospray interface as described (19) .
In parallel, 1-and 3-h fractions were HPLC fractionated. Aliquots of each fraction were preincubated with 51 Cr-labeled HLA-A2-positive, HA-1
Arg EBV-LCL and tested for their ability to reconstitute epitope activity of the HA-1
His -specific T cell clone 5W38 at an E:T ratio of 10:1.
Streptolysin O peptide transport assay
In vitro assays of TAP-mediated peptide transport were performed as previously described (20) . In short, serial dilutions of peptides of interest were tested for their ability to compete for TAP-dependent translocation of a 125 I-iodinated model peptide in streptolysin O-permeabilized EBV-LCLs. The results were expressed as IC 50 values.
Class I MHC-peptide binding and dissociation assay
The dissociation rates of the recombinant-HLA-A2 molecules complexed with fluorescent peptides VLHDDLC*EA, VLRDDLC*EA, VLFDDLC*EA, VLCitDDLC*EA were determined using size exclusion HPLC. Cit were performed at 37°C. Regression analyses on the percentages HLA-A2-bound peptide at the different time points were executed using the two-phase exponential decay model in GraphPad Prism software (version 4.02).
HLA-A2 binding was tested using a quantitative assay based on the inhibition of binding of the fluorescent-labeled standard peptide FLPSDFC*FPSV as described before (21) . In short, various doses of the tested peptides were incubated in the presence of 1 nM fluorescent standard peptide, HLA-A2, and 150 nM ␤ 2 -microglobulin for 1 day at room temperature in the dark in a volume of 100 l, yielding ϳ40 -60% HLAbound fluorescent standard peptide. The percentage of HLA-bound fluorescence was determined after size exclusion chromatography, as described. The IC 50 concentrations were deduced for each peptide by using one-site competition nonlinear regression analysis with the GraphPad Prism software.
Production of recombinant HLA-A2-peptide complexes for crystallographic studies
Both HLA-A2 and ␤ 2 -microglobulin chains were produced as previously described by Garboczi et al. (22) and Bodinier et al. (23) . In brief, the A245V mutant of the HLA-A2 H chain tagged in C-ter with a biotinylation sequence was cloned into pHN1 expression vector as described in Bodinier et al. (23) . Recombinant proteins were produced as inclusion bodies in Escherichia coli XA90FЈLaqQ1 strain. The inclusion bodies were resuspended in 8 M Urea, 50 mM MES (pH 6.5), 0.1 mM DTT, 0.1 mM EDTA, incubated overnight at 4°C and centrifuged 30 min at 100,000 ϫ g. The supernatant was collected and frozen at Ϫ80°C. The HLA-peptide complex refolding step was done by flash dilution of a mix of 21 mg of HLA-A2, 10 mg of ␤ 2 -microglobulin and 10 mg of the desired synthetic peptide into 350 ml of 100 mM Tris (pH 8.0), 400 mM L-arginine HCl, 2 mM EDTA, 5 mM reduced glutathione, 0.5 mM oxidized glutathione, 2 Complete EDTA-free Cocktail Inhibitor tablets (Roche Diagnostics). The refolding solution was subsequently incubated for 4 -5 days at 4°C and concentrated with a 10-or 30-kDa cutoff membrane (Vivacell system; Vivascience). The MHC-peptide complex was purified on a MonoQ 5/50 (GE Healthcare BioScience) column with an FPLC system (Purifier 10; GE Healthcare BioScience) equilibrated in a 10 mM Tris (pH 8.0) buffer. The complex was eluted with 100 -150 mM NaCl and concentrated on Amicon-10 or Amicon-30 to reach a final protein concentration of 2.5-3.5 mg/ml.
Crystallization and data collection
The crystals were obtained using a vapor diffusion technique at 20°C and microseeding. The three HLA-A2/HA-1 complexes were crystallized in presence of 12-15% w/v PEG 6000, 0.1 M NaCl and 0.1 M tri-sodium citrate (pH 6.5). Before x-ray diffraction experiments, crystals were soaked into the crystallization solution to which PEG 6000 was added to reach 30% w/v concentration and flash cooled in liquid nitrogen. Data were collected at European Synchrotron Radiation Facilities (Grenoble, France) on either beamline ID29 or ID23. Complete data sets processing was performed using XDS package (24) . Crystals belong to space group P2 1 and contain one HLA-A2/HA-1 complex per asymmetric unit (see data in supplemental Table S1 ). 6 
Structure determination and refinement
The structures were determined by molecular replacement using the program AMoRe (25) and with HLA-A2/MAGE-A4 structure as search model (Protein Data Bank no. 1I4F (26)). Structures of HLA-A2/HA-1 complexes were refined using iterative cycles of manual rebuilding with O (27) or Coot (28) and refinement with REFMAC5 (29) included in CCP4 package (30) . Final and detailed refinement statistics are summarized (see supplemental data in Table S1 ). 6 The coordinates have been deposited in the Protein Data Bank under entry codes 3FT3 (HLA-A2/HA-1 His ), 3FT4 (HLA-A2/HA-1 Arg ), and 3FT2 (HLA-A2/HA-1 Cit ).
Results
Proteasome-mediated digestion results in equal amounts of HA-1 His and HA-1 Arg nonameric peptides
Proteasome-mediated digestion was analyzed for its impacts on the absence of the nonimmunogenic HA-1 Arg minor histocompatibility Ag at the surface of cells expressing HLA-A2 molecules. Indeed, degradation by proteasomes is the major pathway for the antigenic peptide generation in the cytosol (31) . Because the HA-1
His minor histocompatibility Ag production is proteasome-dependent (see supplemental data in Fig. S2 ), 6 proteasome-mediated cleavage experiments in combination with tandem mass spectrometry were conducted to investigate differential cleavage of the HA-1
His and HA-1 Arg alleles. The digested products of both the 28-meric HA-1
His and the HA-1 Arg peptide contained significant and similar material amounts exactly corresponding to the mass of both nonameric peptides using both constitutive (HeLa) and immunoproteasomes (EBV-LCL) (Table I) (also see supplemental Fig.  S2) . 6 Indeed, 1% of detected relevant fragments is sufficient to be effectively processed for MHC class I presentation (19, 32, 33 The very low level of the HLA-A2/HA-1 Arg peptide complex on the cell surface may be caused by its dissociation rate. We therefore compared the HA-1
His and HA-1 Arg peptide dissociation rates in a competition-based cell-free HLA binding assay using recombinant HLA-A2 molecules and fluorescent analogs of the HA-1 His and HA-1
Arg peptides (Fig. 1) . HLA-A2/HA-1 His complexes are relatively stable at room temperature (t 1/2 ϭ 2593 min). In contrast, the HLA-A2/HA-1 Arg complexes dissociated rapidly (t 1/2 ϭ 29 min) and no intact HLA-A2/HA-1 Arg complexes were found after 2 h. These relative differences in dissociation rates between the two HA-1 alleles were also observed at 37°C (t 1/2 ϭ 536 min for HA-1 His and t 1/2 ϭ 8 min for HA-1 Arg ) (Table III) . Thus, a high dissociation rate of the HA-1
Arg peptide, as compared with that of the HA-1 His peptide, may account for the absence of the HA-1 Arg peptide presented by HLA-A2 on the cell surface.
Binding characterization of the HA-1 peptide variants
We questioned whether the high HA-1 Arg peptide off-rate might be caused by either steric hindrance induced by the arginine side chain size or by the arginine guanidium group positive charge at position 3. In this experiment, we substituted HA-1 peptide position 3 by a phenylalanine (HA-1 Phe ) or by a citrulline (HA-1 Cit )
residue. The results of the competition-based binding assay showed a slightly stronger interaction with the HLA-A2 molecules for HA-1 Phe as compared with HA-1 His (Fig. 1C) (Table III) . If all HA-1 variants are assumed to adopt the same side chain conformation at position 3, these binding data suggest that the side chain size could not directly account for the HA-1
Arg allele instability because both HA-1
Cit and HA-1 Phe peptides are more stable than the HA-1 His peptide. They also indicate that the positive charge removal by substitution of the arginine residue by a citrulline residue seems to enhance the stability of the HLA-A2/HA-1 complex dramatically. Structural data presented below show that the citrulline side chain adopts a different conformation and lead to a completely different interpretation of the binding data.
Crystal structure determination of the HLA-A2/HA-1 His , HLA-A2/HA-1 Arg , and HLA-A2/HA-1 Cit complexes
To elucidate the structural bases for the difference in the HA-1 peptide binding capacities, the structures of HLA-A2 in complex with HA-1 His , HA-1 Arg , and HA-1 Cit have been determined by x-ray crystallography at 1.95, 1.90, and 1.80 Å resolution, respectively. Overall, the peptide backbones are very well defined in the electron density (Fig. 2, A-C) and their conformations are similar for the three HA-1 variants with root mean square differences on C␣ positions ranging from 0.23 Å to 0.41 Å (the superposition is performed on the HLA-A2 ␣1␣2 domain). This conformation is closest to the one adopted by the HIV p17 Gag peptide (SLYN-TVATL, Protein Data Bank entry 1T21 (35) (Fig. 2D) . The histidine ring is almost exactly superimposed on the Tyr 3P aromatic ring of HLA-A2-p17 Gag complex. The HA-1
Arg arginine side chain is roughly superposed to that of the histidine in HA-1 His , with its guanidium group pointing toward the surface (Fig. 2E) . Up to the N atom, it superposes fairly well the Lys 3P of HIV-1 reverse transcriptase peptide (residues 309 -317) bound to HLA-A2 (Protein Data Bank entry 1hhj (37)). However, its electron density is much weaker than that of the HA-1
His variant, indicating an increased mobility. Accordingly, the arginine side chain atomic occupancy had to be set to 0.5 for the HA-1 Arg variant refinement, whereas a full occupancy was used for the HA-1
His and HA-1 Cit variants. The arginine side chain contacts the same HLA-A2 amino acids and its solvent accessible surface is rather limited (25 Å 2 of solvent accessible surface). The citrulline side chain conformation differs unexpectedly from that adopted by the arginine. It is buried in the HLA-A2 peptide binding groove (only 4 Å 2 of solvent accessible surface) and points toward the bottom of the peptide binding groove, the Cit3 P O1 atom forming one hydrogen bond with His 114H N␦1 and the Cit3 P N making a special hydrogen bond with the -electron of Tyr 99H aromatic ring (Fig. 2F) . Its electron density is very well defined all along the side chain, corroborating its stabilization through a dense network of interatomic interactions. Overall, the structural impact of the histidine/arginine polymorphism on the peptide structure is limited to a small systematic shift of the peptide toward the ␣1 HLA-A2 helix. This shift is consistent with the larger size of the arginine side chain. However, the D pocket seems not optimal to welcome the arginine side chain: the charge of the guanidium group is neither compensated by negatively charged HLA-A2 residues nor by a hydrogen bond network. Moreover, there is a moderate but significant steric hindrance generated by short contacts between the Arg 3P C␦ and N atoms and the Leu 156H C␦2 (3.19 and 3.09 Å, respectively) and the Arg 3P N NH group pointing toward the hydrophobic Leu 156H (Fig. 2E) . Last, despite their size and chemical similarities, the arginine and the citrulline do not interact with the same HLA-A2 amino acids and this difference will impact the analysis of the binding data mentioned.
The analysis of the thermal displacement parameters (B-factors) shows that comparatively to the HLA-A2 ␣1␣2 domain, the HA-1
Cit variant is the most stable and the HA-1 Arg peptide the most mobile variant (Fig. 3) , corroborating the observed electron density. The difference is the most contrasted at position 3, for which the citrulline is even slightly more stable than the ␣1␣2 HLA domain, whereas the histidine is almost as stable as the ␣1␣2 domain and the arginine much more mobile. These B-factors are very consistent with the number of contacts that side chains at position 3 establish with the HLA-A2 molecule: the one that forms the largest number of contacts with the HLA-A2 molecule and that is the less exposed to the solvent, i.e., the HA-1
Cit variant, is also the most stable.
Discussion
The observed unidirectional immunogenicity of the di-allelic minor histocompatibility Ag HA-1 locus restricts its usage for immunotherapeutic purposes to the one immunogenic HA-1
His allele. Therefore, we aimed at analyzing the cause of the HA-1 allele differential immunogenicity. Most di-allelic minor histocompatibility Ags display a unidirectional immune response (38) and the phenomenon of "one-allele immunogenicity" can generally be attributed to the lack of peptide presentation at cell surface. The latter can result from gene deletion (i.e., the minor histocompatibility Ag UGT2B17 (39)), from frame-shifts due to nucleotide insertion (i.e., the minor histocompatibility Ag LRH-1 (40)), from alternative splicing (i.e., the minor histocompatibility Ag ACC-6 (41)), or from the introduction of a translation termination codon (i.e., the minor histocompatibility Ag PANE1 (42)). Other mechanisms responsible for one-allele immunogenicity are due to cell biological processes such as differential Ag processing by the proteasome (i.e., the minor histocompatibility Ag HA-3 (43)) and differential Ag transport into the ER by TAP (i.e., minor histocompatibility Ag HA-8 (44)).
So far, the HA-1 Arg allele nonimmunogenicity has remained unexplained. Our results rule out a role for proteasome-mediated cleavage resulting in the absence of the HA-1
Arg peptide at the cell surface because no differential effect of the HA-1 His/Arg polymorphism on proteasome-mediated digestion was observed. Our results on cleavage sites are in line with previous findings that once the relevant peptides are generated by proteasome mediated cleavage, other cleavage sites found within the epitope weigh less heavily for functional peptides cell surface presentation (19) . Moreover, as the exact lengths of HLA-A2 binding nonameric peptides were generated by proteasomes, it was not necessary to study the possibility of an impact of the HA-1 His/Arg polymorphism on N-terminal trimming by amino peptidases in the ER (45) (46) (47) (48) . Our data also clearly indicate that the loss of HA-1 Arg surface presentation is not caused by differential TAP translocation.
Low binding affinity to HLA-A2 molecules certainly influences the absence of detectable HA-1
Arg peptide amounts on the cell surface. The HA-1
Arg peptide binds with 27-fold lower affinity to recombinant HLA-A2 molecules as compared with the HA-1 His peptide. Although peptide binding to recombinant HLA molecules may not always be representative for intracellular peptide binding to TAP-associated HLA molecules in the ER, a 10-fold lower affinity to intracellular TAP-associated HLA-A2 has also been estimated for the HA-1 Arg peptide (data not shown). Because both assays detect the net result of association and dissociation, the lower affinity of HA-1
Arg for HLA-A2 is likely the result of its 90-fold higher dissociation rates as compared with the HLA-A2/ HA-1 His complexes. Given the cell surface presentation of 80 HA-1
His peptides per cell (6) , the affinity differences between the two HA-1 alleles is insufficient to explain the lack of the HA-1
Arg presentation because peptide density at the cell surface is not necessarily correlated with their MHC binding affinity (49) . Moreover, when compared with other HLA-A2 bound peptides, HA-1 His peptide can be considered as a high binder (IC 50 Ͻ 50 nM) and HA-1
Arg as moderate binder (50 nM Ͻ IC 50 Ͻ 500 nM (14)), both being in the affinity range usually observed for effective T cell epitopes. Even low affinity peptides can represent important T cell epitopes (50, 51) , most probably slowly dissociating from the MHC, thereby having sufficient Ag on the cell surface. Therefore, the 90-fold increase in dissociation rate is clearly identified as the main reason for the lack of immunogenicity for HA-1
Arg allele, as it has been already observed for other peptide-MHC complexes (15) . The magnitude of the increased dissociation rate for HA-1 Arg clearly accounts for the lack of HLA-A2/HA-1
Arg complexes at the cell surface. Most likely, the HLA-A2/HA-1
Arg complexes already dissociate intracellularly and never reach the cell surface.
The fast dissociation observed for the HA-1 Arg does not prevent the formation of HLA-A2/HA-1 Arg crystals at room temperature. This indicates that in the crystallization solution, the complex halflife should be at least as long as the time needed for the crystals to appear in the drops, estimated to last 1-3 days. It confirms that the HLA-A2/HA-1 complex half-life depends on the temperature, as exemplified by Table III and previous experiments that showed that the HA-1
His affinity at 20°C is comparable to that of HA-1
Arg at 4°C (7) . It also suggests that the chemical composition of the protein solution may have an impact. The structural data on the two naturally occurring HA-1 allelic peptides and the artificial HA-1
Cit variant provide a clear rationale for these binding data. All peptides bind HLA-A2 with a similar backbone conformation, albeit with different level of flexibility. More quantitatively, the B-factor analysis shows that the average B-factors for the HA-1
Arg , HA-1 His , and HA-1 Cit peptides are 37%, 16%, and 11% higher than that of the HLA-A2 ␣1␣2 domain, respectively. The difference is more contrasted at position 3 (Fig. 3) . The analysis of the interactions between the peptide and the HLA-A2 molecule indicates that the HA-1
Cit variant establishes the largest number of hydrogen bonds and van der Waals contacts (15 hydrogen bonds and 54 C-C contacts Ͻ4 Å), followed by the HA-1
His peptide (14 hydrogen bonds and 47 C-C contacts Ͻ4 Å), whereas the HA-1
Arg peptides is the less tightly bound (12 hydrogen bonds and 39 C-C contacts Ͻ4 Å). This number of contacts correlate very well with the stability data; high peptide offrates correspond to complexes in which less energy is involved in the dissociation, i.e., in which fewer interactions have to be broken to dissociate the peptide from the HLA-A2 molecule. Indeed, the lower number of contacts, the high mobility of the arginine in HA-1
Arg peptide suggested by the crystallographic data and the steric hindrance generated by the close contacts between Arg 3P and Leu 156H are corroborating an extremely rapid HLA dissociation rate for the HA-1
Arg peptide when compared with the HA-1 His peptide. Replacing histidine and arginine residues while maintaining or slightly increasing the size of the substituted amino acids by using HA-1 Phe and HA-1 Cit variants respectively, leads to a significant increase in t 1/2 values. For the HA-1
Phe variant bound to HLA-A2, the phenylalanine side chain conformation is likely to be very close to that adopted by the histidine in HA-1 His peptide. Indeed, among the peptide-HLA-A2 complexes deposited with the Protein Data Bank and whose peptide backbone conformation is similar to that adopted by HA-1 His peptide, aromatic residues (phenylalanine, or tyrosine in Protein Data Bank entries 2V2X (52) and 1T21 (35)) can be found at position 3. These residues also fill the D pocket with a conformation very similar to the one adopted by either the histidine or the arginine in HA-1. In this context, burying a slightly larger and hydrophobic aromatic ring in the HLA-A2 D pocket enhances the HA-1 binding as exemplified by the binding data. Because HA-1
Arg and HA-1 Cit variants adopt very different side chain conformation for position 3, the difference observed in binding properties cannot be attributed to the sole difference in net charge. Due to its positive charge, the arginine cannot adopt the conformation observed for the citrulline side chain. The His 114H , which is hydrogen bonded to the citrulline side chain (Fig. 2F) is positively charged at the crystallization (pH 6.5) and the His 114H N␦1 atom is certainly protonated because the His 114H N2 atom is not as it is involved in a hydrogen bond with the protonated N2 of Arg 97H . As a result, the presence of an arginine in place of the observed citrulline would be electrostatically very unfavorable. Therefore, the increased HA-1
Cit variant half-life is certainly due to the larger number of interactions formed by citrulline side chain that plunges more deeply into the HLA-A2 D pocket. The arginine guanidium group positive charge per se is not responsible for the increased the HA-1
Arg peptide instability because an immunogenic peptide bearing a lysine at position 3 bound in the D pocket has already been observed (Protein Data Bank entry 1HHJ (37)). It just prevents the arginine to adopt the very stable conformation adopted by the citrulline.
Serendipitously, binding and structural data on HA-A1 Cit clearly demonstrate that the citrulline in position 3 behaves as an additional anchor in the HLA-A2 binding groove. Its conformation is reminiscent of that of the arginine side chain in the HLA-B8-restricted EBV epitope (FLRGRAYGL), when bound to HLA-B8 (Protein Data Bank entry 1m05 (53)). In HLA-B8, a lysine or an arginine at position 3 constitutes a main anchor. Because the three first amino acid conformations are very conserved in nonapeptide-HLA-A2 complex structures determined so far, introducing a citrulline at position 3 may constitute a quite general approach to further stabilize a nonapeptide in the HLA-A2 peptide groove. The structural data presented here show that this change has almost no impact on the peptide backbone conformation, and suggest that T cells could thus be likely cross-reactive for HLA-A2-restricted nonapeptide citrulline variants at position 3. We show for the first time functional peptide processing studies combined with the fully concordant HLA-A2/peptide crystallographic data that are explaining the lack of immunogenicity of one of two allelic peptides. Structural basis for this change of stability have been unveiled. It strongly suggests that the HLA-A2/HA-1 His and HLA-A2/HA-1
Arg complexes have a half-life, respectively, above and below a threshold defining the immunologic fate of a subtle different peptide variant. It emphasizes that the use of HLA-A2-restricted HA-1-based immunotherapy is restricted to HA-1 His patients and that other targets should be identified for the patients bearing the HA-1 Arg allele. Finally, the present data demonstrate how combined functional and structural information on peptides before application in immunotherapeutic tumor therapy are essential to ensure optimal cellular immune responses.
